GNI Group

2160.TSE

14.59 USD

0.45

+3.18%

Overview

Last close

14.59 usd

Market cap

730.49M usd

52 week high

25.86 usd

52 week low

10.71 usd

Target price

25.7 usd

Valuation

P/E

22.4039

Forward P/E

N/A

Price/Sales

4.6667

Price/Book Value

3.0234

Enterprise Value

654.05M usd

EV/Revenue

4.15

EV/EBITDA

31.5887

Key financials

Revenue TTM

157.84M usd

Gross Profit TTM

98.41M usd

EBITDA TTM

10.31M usd

Earnings per Share

0.91 usd

Dividend

N/A usd

Total assets

447.52M usd

Net debt

-18.61M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.